Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

TIMOLOL MALEATE

All products: general benefit

Other products in the same Health Canada class (S01ED) — coverage varies; not interchangeable

  • Betaxolol (Betoptic S): general benefit
  • Levobunolol (Betagan): general benefit
  • Brimonidine + timolol (Apo-Brimonidine-Timop): limited Use 310, 393
  • Brinzolamide + timolol (Azarga): limited Use 310, 393
  • Dorzolamide + timolol (Cosopt): limited Use 310, 393
  • Latanoprost + timolol (Xalacom): limited Use 310, 393

11 more in the class list below

Timoptic-XE · DIN 02171899 · 0.5% · Oph Gellan Sol

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Timoptic-XE (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Timoptic-XE · DIN 02171899 Manufacturer: Elvium Life Sciences; listing date 1996-10-01 Health Canada: Marketed since 2020-09-02 · brand TIMOPTIC-XE · ATC S01ED01 TIMOLOL · form Solution (extended-release) · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.5 % · company Elvium life sciences · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $3.5320 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18778 · Verify on the e-Formulary ↗ (DIN 02171899)

Source record
DIN 02171899: Timoptic-XE Raw flags: sec3=Y Item: 523600081; group id 641; item number 1615; lccId None; manufacturer id ELV Source form: Oph Gellan Sol; strength: 0.5% Recorded listing: General benefit Source prices (unrounded): $9.3115; ministry $3.5320 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02171899 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18778 Therapeutic Notes (formulary) Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.
Interchangeable products
Timolol Maleate-EX · DIN 02242276 · $3.5320
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (52:36 Other Eye, Ear, Nose and Throat Agents) and how they are covered

Matched class: 52:36 Other Eye, Ear, Nose and Throat Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BETAXOLOL HCL, DICLOFENAC SODIUM, LEVOBUNOLOL HCL Some products covered without a code (check the product listing): ACETAZOLAMIDE, METHAZOLAMIDE, SODIUM CROMOGLYCATE 52:36 Other Eye, Ear, Nose and Throat Agents

BETAXOLOL HCL

· 1 products · General benefit · strengths: 0.25% · Oph Susp

LEVOBUNOLOL HCL

· 1 products · General benefit · strengths: 0.5% · Oph Sol

BRIMONIDINE TARTRATE & TIMOLOL MALEATE

· 3 products · Limited Use, codes 310, 393 · strengths: 0.2% & 0.5% · Oph Sol-10mL Pk

BRINZOLAMIDE & TIMOLOL MALEATE

· 1 products · Limited Use, codes 310, 393 · strengths: 1% & 0.5% · Oph Susp-5mL Pk

DORZOLAMIDE HCL & TIMOLOL MALEATE

· 11 products · Limited Use, codes 310, 393 · strengths: 2% & 0.5% · Oph Sol, Oph Sol-0.2mL Pk

LATANOPROST & TIMOLOL MALEATE

· 9 products · Limited Use, codes 310, 393 · strengths: 50mcg/mL & 5mg/mL · Oph Sol-2.5mL Pk

TIMOLOL MALEATE & TRAVOPROST

· 4 products · Listed, not a benefit (1), Limited Use, codes 310, 393 (3) · strengths: 0.5% & 0.004% · Oph Sol, Oph Sol-5mL Pk

ACETAZOLAMIDE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 250mg · Tab

METHAZOLAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg · Tab

BIMATOPROST

· 8 products · Listed, not a benefit (1), Limited Use, codes 171, 172, 387 (7) · strengths: 0.03%, 0.01% · Oph Sol, Oph Sol-5mL Pk, Oph Sol-7.5mL Pk

BRIMONIDINE

· 7 products · Limited Use, codes 171, 172, 387 · strengths: 0.15%, 0.2% · Oph Sol

BRINZOLAMIDE

· 1 products · Limited Use, codes 171, 172, 387 · strengths: 1% · Oph Susp Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:36 and 20 more
Full class listing Related classes: 52:04 Anti-Infectives, 52:08 Anti-Inflammatory Agents, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: elevated intraocular pressure
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. BIMATOPROST · Listed, not a benefit (1), Limited Use, codes 171, 172, 387 (7)  the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension PM: https://pdf.hres.ca/dpd_pm/00049647.PDF; date January 28, 2019; DIN 02429063; fetched 2026-09-10 Product monograph BRINZOLAMIDE · Limited Use, codes 171, 172, 387 • the treatment of elevated intraocular pressure (IOP) in adult patients with ocular hypertension or open-angle glaucoma. PM: https://pdf.hres.ca/dpd_pm/00069562.PDF; date OCT 23, 1998; DIN 02238873; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS TIMOPTIC® (timolol maleate ophthalmic solution, USP) is indicated for:  the reduction of elevated intraocular pressure 1.1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada, therefore, an indication for pediatric use has not been authorized. 1.2 Geriatrics Geriatrics (>65 years of age): Evidence from experience in geriatric populations does not suggests significant differences in safety and effectiveness. https://pdf.hres.ca/dpd_pm/00067983.PDF PM date: OCT 28, 2016 Source product: TIMOPTIC; DIN 00451207; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.